Salivary Dysfunctions and Consequences After Radioiodine Treatment for Thyroid Cancer: Protocol for a Self-Controlled Study (START Study)

Clémence Baudin, Charlotte Lussey-Lepoutre, Alice Bressand, Camille Buffet, Fabrice Menegaux, Marine Soret, David Broggio, Céline Bassinet, Christelle Huet, Gemma Armengol, Laurence Leenhardt, Marie-Odile Bernier, Clémence Baudin, Charlotte Lussey-Lepoutre, Alice Bressand, Camille Buffet, Fabrice Menegaux, Marine Soret, David Broggio, Céline Bassinet, Christelle Huet, Gemma Armengol, Laurence Leenhardt, Marie-Odile Bernier

Abstract

Background: Following radioiodine (131I) therapy of differentiated thyroid cancer, the salivary glands may become inflamed, leading to dysfunctions and decreases in patients' nutritional status and quality of life. The incidence of these dysfunctions after 131I-therapy is poorly known, and no clinical or genetic factors have been identified to date to define at-risk patients, which would allow the delivered activity to be adapted to the expected risk of salivary dysfunctions.

Objective: The aims of this study are to estimate the incidence of salivary dysfunctions, and consequences on the quality of life and nutritional status for patients after 131I-therapy; to characterize at-risk patients of developing posttreatment dysfunctions using clinical, biomolecular, and biochemical factors; and to validate a dosimetric method to calculate the dose received at the salivary gland level for analyzing the dose-response relationship between absorbed doses to salivary glands and salivary dysfunctions.

Methods: This prospective study aims to include patients for whom 131I-therapy is indicated as part of the treatment for differentiated thyroid cancer in a Paris hospital (40 and 80 patients in the 1.1 GBq and 3.7 GBq groups, respectively). The follow-up is based on three scheduled visits: at inclusion (T0, immediately before 131I-therapy), and at 6 months (T6) and 18 months (T18) posttreatment. For each visit, questionnaires on salivary dysfunctions (validated French tool), quality of life (Hospital Anxiety and Depression scale, Medical Outcomes Study 36-Item Short Form Survey), and nutritional status (visual analog scale) are administered by a trained clinical research associate. At T0 and T6, saliva samples and individual measurements of the salivary flow, without and with salivary glands stimulation, are performed. External thermoluminescent dosimeters are positioned on the skin opposite the salivary glands and at the sternal fork immediately before 131I administration and removed after 5 days. From the doses recorded by the dosimeters, an estimation of the dose received at the salivary glands will be carried out using physical and computational phantoms. Genetic and epigenetic analyses will be performed to search for potential biomarkers of the predisposition to develop salivary dysfunctions after 131I-therapy.

Results: A total of 139 patients (99 women, 71.2%; mean age 47.4, SD 14.3 years) were enrolled in the study between September 2020 and April 2021 (45 and 94 patients in the 1.1 GBq and 3.7G Bq groups, respectively). T6 follow-up is complete and T18 follow-up is currently underway. Statistical analyses will assess the links between salivary dysfunctions and absorbed doses to the salivary glands, accounting for associated factors. Moreover, impacts on the patients' quality of life will be analyzed.

Conclusions: To our knowledge, this study is the first to investigate the risk of salivary dysfunctions (using both objective and subjective indicators) in relation to organ (salivary glands) doses, based on individual dosimeter records and dose reconstructions. The results will allow the identification of patients at risk of salivary dysfunctions and will permit clinicians to propose a more adapted follow-up and/or countermeasures to adverse effects.

Trial registration: ClinicalTrials.gov NCT04876287; https://ichgcp.net/clinical-trials-registry/NCT04876287.

International registered report identifier (irrid): DERR1-10.2196/35565.

Keywords: dysfunction; epidemiology; lacrimal gland; protocol; radioiodine; salivary gland; self-controlled study; thyroid cancer.

Conflict of interest statement

Conflicts of Interest: None declared.

©Clémence Baudin, Charlotte Lussey-Lepoutre, Alice Bressand, Camille Buffet, Fabrice Menegaux, Marine Soret, David Broggio, Céline Bassinet, Christelle Huet, Gemma Armengol, Laurence Leenhardt, Marie-Odile Bernier. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 22.07.2022.

Figures

Figure 1
Figure 1
Timeline summarizing the study's outline. T0: enrollment; T6: 6 months after radioiodine (131I) therapy; T18: 18 months after radioiodine therapy.
Figure 2
Figure 2
Thermoluminescent dosimeter position.

References

    1. Mitton N, Remontet L, Bossard N, Colonna M. Estimations départementales de l’incidence des cancers en 2007 à partir des données des registres et des données du programme de médicalisation des systèmes d’information, France. Rev Épidémiol Santé Publique. 2010 Apr;58:S13–S14. doi: 10.1016/j.respe.2010.02.029.
    1. Andresen NS, Buatti JM, Tewfik HH, Pagedar NA, Anderson CM, Watkins JM. Radioiodine ablation following thyroidectomy for differentiated thyroid cancer: literature review of utility, dose, and toxicity. Eur Thyroid J. 2017 Jul;6(4):187–196. doi: 10.1159/000468927. etj-0006-0187
    1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1–133. doi: 10.1089/thy.2015.0020.
    1. Van Nostrand D. Sialoadenitis secondary to ¹³¹I therapy for well-differentiated thyroid cancer. Oral Dis. 2011 Mar;17(2):154–161. doi: 10.1111/j.1601-0825.2010.01726.x.
    1. Aliko A, Wolff A, Dawes C, Aframian D, Proctor G, Ekström J, Narayana N, Villa A, Sia YW, Joshi RK, McGowan R, Beier Jensen S, Kerr AR, Lynge Pedersen AM, Vissink A. World Workshop on Oral Medicine VI: clinical implications of medication-induced salivary gland dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Aug;120(2):185–206. doi: 10.1016/j.oooo.2014.10.027.S2212-4403(15)00569-6
    1. Pedersen AML, Sørensen CE, Proctor GB, Carpenter GH, Ekström J. Salivary secretion in health and disease. J Oral Rehabil. 2018 Sep;45(9):730–746. doi: 10.1111/joor.12664.
    1. Solans R, Bosch JA, Galofré P, Porta F, Roselló J, Selva-O'Callagan A, Vilardell M. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med. 2001 May;42(5):738–743.
    1. Hollingsworth B, Senter L, Zhang X, Brock GN, Jarjour W, Nagy R, Brock P, Coombes KR, Kloos RT, Ringel MD, Sipos J, Lattimer I, Carrau R, Jhiang SM. Risk factors of I-induced salivary gland damage in thyroid cancer patients. J Clin Endocrinol Metab. 2016 Nov;101(11):4085–4093. doi: 10.1210/jc.2016-1605.
    1. Rosario PW, Calsolari MR. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin. Thyroid. 2013 May;23(5):617–619. doi: 10.1089/thy.2012.0050.
    1. Grewal RK, Larson SM, Pentlow CE, Pentlow KS, Gonen M, Qualey R, Natbony L, Tuttle RM. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med. 2009 Oct;50(10):1605–1610. doi: 10.2967/jnumed.108.061382. jnumed.108.061382
    1. Klein Hesselink EN, Brouwers AH, de Jong JR, van der Horst-Schrivers ANA, Coppes RP, Lefrandt JD, Jager PL, Vissink A, Links TP. Effects of radioiodine treatment on salivary gland function in patients with differentiated thyroid carcinoma: a prospective study. J Nucl Med. 2016 Nov;57(11):1685–1691. doi: 10.2967/jnumed.115.169888. jnumed.115.169888
    1. Fard-Esfahani A, Mirshekarpour H, Fallahi B, Eftekhari M, Saghari M, Beiki D, Ansari-Gilani K, Takavar A. The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma. Clin Nucl Med. 2007 Sep;32(9):696–699. doi: 10.1097/RLU.0b013e318124fdb6.00003072-200709000-00005
    1. Moreddu E, Baumstarck-Barrau K, Gabriel S, Fakhry N, Sebag F, Mundler O, Chossegros C, Taïeb D. Incidence of salivary side effects after radioiodine treatment using a new specifically-designed questionnaire. Br J Oral Maxillofac Surg. 2017 Jul;55(6):609–612. doi: 10.1016/j.bjoms.2017.03.019.S0266-4356(17)30109-2
    1. Charras A. Altérations du méthylome au cours du Syndrome de Gougerot Sjögren, Doctoral thesis in Immunology. Theses. 2018. [2020-10-14]. .
    1. Chaudhry MA, Omaruddin RA, Kreger B, de Toledo SM, Azzam EI. Micro RNA responses to chronic or acute exposures to low dose ionizing radiation. Mol Biol Rep. 2012 Jul 25;39(7):7549–7558. doi: 10.1007/s11033-012-1589-9.
    1. World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013 Nov 27;310(20):2191–2194. doi: 10.1001/jama.2013.281053.1760318
    1. Xu X, Eckerman K. Handbook of Anatomical Models for Radiation Dosimetry. Milton Park, UK: Routledge; 2009.
    1. Humphrey SP, Williamson RT. A review of saliva: normal composition, flow, and function. J Prosthet Dent. 2001 Feb;85(2):162–169. doi: 10.1067/mpr.2001.113778.S0022-3913(01)54032-9
    1. Miranda-Rius J, Brunet-Llobet L, Lahor-Soler E, Farré M. Salivary secretory disorders, inducing drugs, and clinical management. Int J Med Sci. 2015;12(10):811–824. doi: 10.7150/ijms.12912. ijmsv12p0811
    1. Van Nostrand D, Neutze J, Atkins F. Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med. 1986 Oct;27(10):1519–1527.
    1. Clement SC, Peeters RP, Ronckers CM, Links TP, van den Heuvel-Eibrink MM, Nieveen van Dijkum EJM, van Rijn RR, van der Pal HJH, Neggers SJ, Kremer LCM, van Eck-Smit BLF, van Santen HM. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma--a systematic review. Cancer Treat Rev. 2015 Dec;41(10):925–934. doi: 10.1016/j.ctrv.2015.09.001.S0305-7372(15)00165-6
    1. Leenhardt L, Ménégaux F, Franc B, Hoang C, Salem S, Bernier M, Dupasquier-Fédiaevsky L, Le Marois E, Rouxel A, Chigot J, Chérié-Challine L, Aurengo A. Cancers de la thyroïde. EMC Endocrinologie. 2005 Feb;2(1):1–38. doi: 10.1016/j.emcend.2004.10.003.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir